We therefore assessed the relative DCF-measured ROS levels in these and NPM1 genetic subgroups (cytogenetic/molecular patient characteristics in S1 Table) in the dominant blast population (CD34+ in CD34+AML; n = 70 [29 BM/ 41 PB], or CD34− CD117+ in CD34− AML; n = 23 [10 BM/ 13 PB]). This evidence concerns the gene KIT and acute myeloid leukemia.